High Evidence
Research Overview
Survodutide Research for MASH/NAFLD
An evidence-based overview of research examining Survodutide in the context of mash/nafld. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 RCT (N=293) showed 83% MASH resolution vs 18% placebo and 64.5% fibrosis improvement vs 25.9% placebo. Liver fat reduction of 82-86%. These are the highest MASH resolution rates reported for any drug in Phase 2. Phase 3 ACHIEVE trial ongoing.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for MASH/NAFLD
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Survodutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.